Common TitleDELPHI
Official Title A Phase II, Open-label Trial, to Investigate Pharmacokinetics, Safety, Tolerability and Antiviral Activity of (Darunavir)TMC114/Ritonavir b.i.d in Treatment-Experienced HIV-1 Infected Children and Adolescents
Phase Phase II
ClinicalTrials.gov NCT00355524
Treatments
Darunavir
Darunavir
Tradename:PrezistaOther Names:DRVClass:Protease Inhibitors (PI)Categories PediatricsTreatment-Experienced
Funding
IndustryTibotec Pharmaceuticals, Ireland
References
- Blanche S, Bologna R, Cahn P, et al. Pharmacokinetics, safety and efficacy of darunavir/ritonavir in treatment-experienced children and adolescents. AIDS. 2009;23:2005-13.